Form 4: Ginkgo Bioworks Director Hannan Reports Stock Transactions

Director Kathy Hopinkah Hannan reports acquisition and vesting of restricted stock units and stock options in Ginkgo Bioworks Holdings, Inc.

Summary

• Kathy Hopinkah Hannan, a director of Ginkgo Bioworks Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On June 12, 2024, 105,263 Class A Common Stock shares were acquired upon the vesting of restricted stock units (RSUs) granted on June 16, 2023.
• Following this transaction, Hannan directly owns 167,249 shares of Class A Common Stock.
• On June 13, 2024, Hannan was granted 432,900 restricted stock units and 571,428 stock options.
• The exercise price of the stock options is $0.462.
• These RSUs and stock options will vest on the earlier of June 13, 2025, or the day before the next Annual Meeting of Shareholders, contingent on continued service as a Non-Employee Director.
• The Black-Scholes value of the option award as of the grant date is $200,000.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but the granting of equity could be viewed as a positive sign of alignment between management and shareholders.

Positives

• The vesting of RSUs and granting of new RSUs and stock options to a director could be seen as an incentive aligning the director's interests with those of the shareholders.

Future Outlook

The vesting of RSUs and stock options in the future is contingent on the director's continued service as a Non-Employee Director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The granting of stock options and RSUs is a common practice to incentivize directors and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies, particularly in the biotech sector.
• The size of the grant and vesting schedule are generally aligned with industry benchmarks for companies of similar size and stage of development.
• Comparing Ginkgo Bioworks' director compensation structure with companies like Amyris or Zymergen (prior to its acquisition) would provide a more detailed assessment of its competitiveness.

Stakeholder Impact

• The transactions reported may have a minor impact on shareholders due to the change in ownership by a director.
• The granting of RSUs and stock options incentivizes the director to act in the best interests of the company, potentially benefiting all stakeholders.

Key Dates